IBA and Telix strengthen ties through agreement to distribute ARTMS’s QIS®
IBA and Telix's ARTMS unit agreed to distribute ARTMS's QUANTM® Irradiation System (QIS®) globally. QIS® enables decentralized production of radiometals for theranostics. IBA will offer QIS® to cyclotron customers, aiming to expand theranostics. Both companies aim to advance radiometal-based medicine. IBA is listed on EURONEXT (IBAB.BR, IBAB.BB), Telix on ASX (TLX) and NASDAQ (TLX).
How this was made
The 30-second read
Why it matters
Both companies stand to benefit from expanded market access, though the financial impact will depend on customer uptake and pricing.
Market read
The partnership could boost revenue streams for both firms in the growing theranostics market, offering a modest but actionable trading angle.
What to watch
Potential supply‑chain constraints for isotopes and the need for additional capital investment by customers.
Background
The agreement ties IBA's accelerator expertise with ARTMS's solid‑target cyclotron system, aiming to scale production of key medical isotopes such as gallium‑68 and zirconium‑89.
Ticker impact
Telix's ARTMS unit signed a distribution deal with IBA, extending QIS technology to IBA's cyclotron customers.
likely modest upside as the partnership could boost sales and market penetration.
Telix gains a global distribution partner, potentially accelerating adoption of its gallium‑68 and zirconium‑89 production platform.
Market effects
strengthens the radiopharmaceutical and theranostics equipment sector by linking accelerator hardware with solid‑target technology.
Europe and North America could see increased activity as IBA's global customer base adopts QIS.
moderate, as the partnership affects a niche but growing market for diagnostic isotopes.
Counterpoint
The deal may be over‑hyped; adoption could be slower due to regulatory hurdles and competition from other target technologies.
Key entities
- CompanyIBA
Ion Beam Applications, a leading particle accelerator and radiopharmaceutical solutions provider.
- CompanyTelix Pharmaceuticals
Global radiopharmaceutical company; ARTMS is its subsidiary.
